“We are very happy that the FDA has accepted our IND application to start our Phase 2 study with Oncoral in the US, which is an important step forward for Ascelia Pharma. We believe this daily oral tablet formulation of irinotecan has the potential to provide both better efficacy and improved safety to patients suffering from this very aggressive cancer form where there is a large unmet medical need”, said Carl Bjartmar, Chief Medical Officer of Ascelia Pharma.
In this combination study, Ascelia Pharma’s irinotecan chemotherapy tablet Oncoral (ASC-201) will be evaluated in combination with Taiho Oncology’s LONSURF® (trifluridine and tipiracil) film-coated tablets for oral use. The all-oral combination of Oncoral and LONSURF is investigational at this time and not approved for use in gastric cancer or any other disease.
Following an initial dose-finding part, the Phase 2 study will be a randomized controlled multicenter study of Oncoral added to LONSURF compared to LONSURF alone. The primary endpoint will be progression-free survival, with secondary endpoints including response rate, overall survival, pharmacokinetics, safety, and tolerability.
The study will include approximately 100 patients with metastatic gastric cancer and first patient visit is planned for H1 2022. The initial portion of the planned global study will be conducted at hospitals in Europe, whereas the subsequent randomized part will also include US sites.